This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Clovis Oncology Management

Management criteria checks 3/4

Key information

Patrick Mahaffy

Chief executive officer

US$2.6m

Total compensation

CEO salary percentage	28.0%
CEO tenure	13.9yrs
CEO ownership	0.7%
Management average tenure	7.1yrs
Board average tenure	13.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Patrick Mahaffy's remuneration changed compared to Clovis Oncology's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2022	n/a	n/a	-US$252m
Jun 30 2022	n/a	n/a	-US$263m
Mar 31 2022	n/a	n/a	-US$258m
Dec 31 2021	US$3m	US$739k	-US$265m
Sep 30 2021	n/a	n/a	-US$299m
Jun 30 2021	n/a	n/a	-US$310m
Mar 31 2021	n/a	n/a	-US$336m
Dec 31 2020	US$3m	US$721k	-US$369m
Sep 30 2020	n/a	n/a	-US$370m
Jun 30 2020	n/a	n/a	-US$385m
Mar 31 2020	n/a	n/a	-US$413m
Dec 31 2019	US$7m	US$719k	-US$400m
Sep 30 2019	n/a	n/a	-US$400m
Jun 30 2019	n/a	n/a	-US$396m
Mar 31 2019	n/a	n/a	-US$377m
Dec 31 2018	US$6m	US$689k	-US$368m
Sep 30 2018	n/a	n/a	-US$321m
Jun 30 2018	n/a	n/a	-US$291m
Mar 31 2018	n/a	n/a	-US$366m
Dec 31 2017	US$9m	US$636k	-US$346m
Sep 30 2017	n/a	n/a	-US$365m
Jun 30 2017	n/a	n/a	-US$370m
Mar 31 2017	n/a	n/a	-US$324m
Dec 31 2016	US$789k	US$224k	-US$349m

Compensation vs Market: Patrick's total compensation ($USD2.64M) is above average for companies of similar size in the German market ($USD439.47K).

Compensation vs Earnings: Patrick's compensation has been consistent with company performance over the past year.

CEO

Patrick Mahaffy (59 yo)

13.9yrs

Tenure

US$2,639,083

Compensation

Mr. Patrick J. Mahaffy, M.A., co-founded Clovis Oncology, Inc. in April 20, 2009 and has been its Chief Executive Officer and President since April 20, 2009. Mr. Mahaffy served as the Chief Executive Offic...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Patrick Mahaffy	Co-Founder	13.9yrs	US$2.64m	0.67% € 85.6k
Daniel Muehl	Executive VP & CFO	7yrs	US$1.19m	0.072% € 9.2k
Paul Gross	Executive VP	7.2yrs	US$1.20m	0.068% € 8.7k
Lindsey Rolfe	Executive VP of Clinical Development & Pharmacovigilance and Chief Medical Officer	7.6yrs	US$1.24m	0.078% € 10.0k
Thomas Harding	Executive VP & Chief Scientific Officer	3.4yrs	no data	no data
Ann Bozeman	Executive Vice President of Human Resources	6.5yrs	no data	no data

7.1yrs

Average Tenure

57yo

Average Age

Experienced Management: C6O's management team is seasoned and experienced (7.1 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Patrick Mahaffy	Co-Founder	13.9yrs	US$2.64m	0.67% € 85.6k
Paul Klingenstein	Independent Director	13.9yrs	US$260.00k	0.041% € 5.2k
Brian Atwood	Independent Director	14.2yrs	US$270.00k	0.040% € 5.1k
Edward McKinley	Independent Director	14.2yrs	US$270.00k	0.17% € 22.1k
James Blair	Independent Director	14.2yrs	US$270.00k	0.044% € 5.6k
Ginger Graham	Independent Chairman	10.2yrs	US$287.50k	0% € 0
Thorlef Spickschen	Independent Director	14.2yrs	US$257.50k	0.040% € 5.1k
Ronit Simantov	Director	1.7yrs	US$375.21k	no data
Keith Flaherty	Independent Director	10.2yrs	US$259.58k	0% € 0
Richard Fair	Independent Director	4.4yrs	US$257.50k	0% € 0
Robert Azelby	Independent Director	4.4yrs	US$255.00k	0% € 0

13.9yrs

Average Tenure

66yo

Average Age

Experienced Board: C6O's board of directors are seasoned and experienced ( 13.9 years average tenure).

This company listing is no longer active

Clovis Oncology Management

Management criteria checks 3/4

Key information

Recent management updates

Insufficient new directors

Insufficient new directors

Insufficient new directors

Recent updates

Clovis Oncology, Inc.(OTCPK:CLVS.Q) dropped from NASDAQ Composite Index

Clovis Oncology, Inc.(NasdaqGS:CLVS) dropped from S&P TMI Index

Nasdaq to Delist Common Stock of Clovis Oncology from Exchange

Clovis Oncology, Inc. Filed for Bankruptcy

Clovis Oncology, Inc. Filed for Bankruptcy

Clovis Oncology, Inc. Discusses the Overall Survival (Os) Data from the ARIEL3 Clinical Trial with FDA t

Insufficient new directors

Third quarter 2022 earnings released: US$0.39 loss per share (vs US$0.56 loss in 3Q 2021)

Clovis Oncology, Inc Announces Highlights Updated LuMIERE Phase 1 Data of Targeted Radiotherapy Candidate FAP-2286 at the 35th Annual EANM Congress

Cvis Oncncology, Inc. Announces Positive Top-Line Data from the Phase 3, Open-Label, Multicenter, Randomized Triton3 Trial

Clovis Oncology, Inc. Submits Applications for Rubraca® Label Expansion in the US and European Union as First-Line Maintenance Treatment in Women with Advanced Ovarian Cancer

Clovis Oncology’s Rubraca (Rucaparib) as First-Line Maintenance Treatment Improves Progression-Free Survival in Women with Advanced Ovarian Cancer Across Disease Risk Subgroups

Second quarter 2022 earnings released: US$0.49 loss per share (vs US$0.61 loss in 2Q 2021)

Clovis Oncology, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Clovis Oncology Highlights Phase 1 Data from Ongoing Clinical Studies of Targeted Radiotherapy Candidate FAP-2286 At SNMMI Annual Meeting

First quarter 2022 earnings released: US$0.43 loss per share (vs US$0.64 loss in 1Q 2021)

Now 20% undervalued

Insufficient new directors

Now 20% undervalued after recent price drop

Clovis Oncology, Inc. to Report Q1, 2022 Results on May 04, 2022

Clovis Oncology Highlights Presentations on FAP-2286 and Rubraca® (Rucaparib) at the AACR Annual Meeting 2022

Now 23% undervalued after recent price drop

Clovis Oncology, Inc. Announces A Trial-In-Progress Poster Detailing the Phase 1 Portion of the LuMIERE Clinical Study for Its Targeted Radiotherapy Candidate FAP-2286

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Clovis Oncology, Inc. Provides Preliminary Unaudited Earnings Guidance for the Quarter and Year Ended December 31, 2021

Insufficient new directors

Third quarter 2021 earnings released: US$0.56 loss per share (vs US$0.89 loss in 3Q 2020)

Clovis Oncology, Inc. Announces Availability of and Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Switzerland

Clovis Oncology, Inc. Provides an Update on the Clinical Development Programs

Second quarter 2021 earnings released: US$0.61 loss per share (vs US$1.15 loss in 2Q 2020)

Clovis Oncology Announces LuMIERE Clinical Trial Evaluating Novel Peptide-Targeted Radionuclide Therapy FAP-2286 Now Open for Enrollment

Clovis Oncology, Inc. Highlights Rubraca® (rucaparib) and Lucitanib Data at 2021 ASCO Annual Meeting

First quarter 2021 earnings released: US$0.64 loss per share (vs US$1.39 loss in 1Q 2020)

Clovis Oncology, Inc. Announces First Presentation of Data from the Phase 3 ARIEL4 Study of Rubraca® (rucaparib) at the Society of Gynecologic Oncology Virtual Annual Meeting on Women’s Cancer

Revenue beats expectations

Full year 2020 earnings released: US$4.38 loss per share (vs US$7.43 loss in FY 2019)

Clovis Oncology, Inc. Presents Data in Advanced Prostate Cancer At Asco 2021 Genitourinary Cancers Symposium Virtual Meeting

New 90-day high: €8.10

New 90-day high: €4.77

Clovis Oncology, Inc. to Report Q4, 2020 Results on Feb 23, 2021

Clovis Oncology, Inc. Completes Submission of Two Investigational New Drug Applications to the U.S. Food and Drug Administration for FAP-2286

Clovis Oncology’s Rubraca® (rucaparib) Met the Primary Endpoint of Significantly Improving Progression-Free Survival vs. Chemotherapy in the ARIEL4 Randomized Phase 3 Treatment Study in Later-line Ovarian Cancer Patients with a BRCA mutation

Third quarter 2020 earnings released: US$0.89 loss per share

Revenue misses expectations

Clovis Oncology, Inc. announced that it expects to receive $50 million in funding

New 90-day low: €3.78

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age